A RETROSPECTIVE STUDY ON THE IMPACT OF COMORBID MEDICAL CONDITIONS ON PSYCHIATRIC DIAGNOSIS AND TREATMENT.

Farheen Fatma[a], Dhruv[b,*]

[a] *Assistant Professor, Department of Psychiatry, Netaji Subhas Medical College and Hospital, Amhara, Bihta, Bihar, India*

[b] *Tutor, Department of Anatomy, All India Institute of Medical Sciences, Patna, Bihar, India*

Abstract.

Objectives:

This study aimed to analyze the effect of comorbid scientific situations on the accuracy of psychiatric prognosis and the effectiveness of psychiatric remedies. Specifically, this study aimed to evaluate how comorbid scientific conditions impact the diagnostic process and treatment effects for patients with psychiatric issues.

Materials and Methods:

The study retrospectively analyzed electronic medical data from a large psychiatric sanatorium over five years. 200 patients with various psychiatric disorders were identified and divided into two groups: those with comorbid scientific situations (n=100) and those without comorbid clinical conditions (n=100). Data on demographic traits, psychiatric diagnoses, medical comorbidities, prescribed medicines, and treatment results was collected. Statistical analyses protected chi-square tests, logistic regression, and analysis of variance (ANOVA) to examine the two corporations.

Results:

Comorbid medical situations considerably impacted psychiatric prognosis and treatment. Patients with comorbid clinical conditions were more likely to not acquire on-time psychiatric diagnoses than those without scientific comorbidities ($p<0.05$). Additionally, patients with comorbidities had been prescribed a more excellent range of medications. They had a better rate of polypharmacy, which improved the chance of destructive drug interactions and facet consequences ($p<0.01$). Treatment effects, such as symptom reduction and exceptional life development, were less favorable for patients with comorbid clinical conditions ($p<0.001$).

Conclusion:

Comorbid medical conditions significantly affect the accuracy of psychiatric diagnoses and the effectiveness of psychiatric remedies. Healthcare vendors must be vigilant in assessing and dealing with comorbid medical conditions while diagnosing and treating psychiatric disorders to improve affected person results. This study highlights the want for a multidisciplinary technique that considers each psychiatric and clinical aspect of care to optimize the well-being of patients with comorbid psychiatric and medical conditions.

Recommendations:

Further research is warranted to discover specific strategies for incorporated care and increase pointers for managing comorbidities in psychiatric settings.

Keywords: psychiatry, diagnosis, treatment, comorbidities, outcomes, integrated care, Submitted: 2023-09-22, Accepted: 2023-09-26

1. INTRODUCTION.

Psychiatric disorders encompassing a broad spectrum of mental health conditions significantly burden patients, families, and societies worldwide. These conditions, including depression, anxiety disorders, schizophrenia, bipolar disorder, and posttraumatic stress disorder, affect the cognitive, emotional, and behavioral facets of patients' lives [1]. Achieving accurate psychiatric diagnoses and effective treatment are pivotal to improving the well-being and quality of life of those grappling with these disorders. However, psychiatric care is often complicated by the presence of comorbid medical conditions, adding a layer of complexity to the diagnostic and therapeutic processes [2]. This intricate interplay between psychiatric and medical illnesses raises critical questions about how comorbidities impact the accuracy of psychiatric diagnoses and psychiatric treatment outcomes [3].

Comorbidity, the coexistence of two or more medical or psychiatric conditions within the same individual, is a common phenomenon in clinical practice. A growing body of evidence suggests that comorbid medical conditions can profoundly influence psychiatric diagnosis and treatment [4]. The implications of comorbidities extend beyond mere diagnostic challenges, encompassing aspects such as the choice of medications, the management of drug interactions, treatment adherence, and, ultimately, the effectiveness of interventions [5]. Understanding the intricate relationships between psychiatric and medical comorbidities is essential not only for clinicians striving to provide holistic care but also for policymakers, healthcare administrators, and researchers aiming to enhance healthcare delivery systems [6]. This study explores the impact of comorbid medical conditions on psychiatric diagnosis and treatment, shedding light on the multifaceted dynamics that shape the course of care for patients confronting the confluence of psychiatric and medical challenges.

*Corresponding author.
Email address: dhruvs958@gmail.com (Dhruv)

2. MATERIALS AND METHODS.

2.1. ***Study Design and Population.***

To comprehensively determine the impact of comorbid medical situations on psychiatric analysis and treatment, this study applied a retrospective analysis of digital scientific information from a prominent psychiatric sanatorium. A cohort of 200 patients who had obtained psychiatric diagnoses over a 5-year length was recognized. The patients were divided into two distinct businesses: people with comorbid clinical situations (n=100) and people without comorbid clinical conditions (n=100). Demographic characteristics such as age, gender, race, and socioeconomic popularity have been accrued for each affected person. These variables served as essential covariates in our analyses, as they may affect the presence of comorbid medical conditions and the consequences of psychiatric care. By obtaining and carefully controlling for these demographic factors, we aimed to ensure the validity and reliability of our findings, minimizing the threat of confounding variables affecting the results.

2.2. ***Psychiatric Diagnoses and Medical Comorbidities.***

For every affected person in the study, records on their psychiatric diagnoses and comorbid clinical conditions from the electronic medical records were retrieved. Psychiatric diagnoses had been categorized in keeping with installed diagnostic criteria, including the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Medical comorbidities encompassed an extensive range of conditions, inclusive of, however not confined to, cardiovascular diseases, diabetes, breathing disorders, and autoimmune sicknesses.

2.3. ***Prescribed Medications.***

To investigate the impact of comorbid scientific conditions on prescribed medicinal drugs, we compiled a comprehensive listing of the medicines every patient obtained as part of their psychiatric treatment. This protected psychotropic medications along with antidepressants, antipsychotics, anxiolytics, and temper stabilizers. In addition,

we recorded any medicines prescribed to manipulate comorbid clinical situations, developing a detailed profile of the pharmacological interventions for each patient.

2.4. ***Treatment Outcomes.***

Treatment consequences were evaluated through diverse measures, including the discount of psychiatric signs and symptoms and enhancements in universal pleasant lifestyles. These measures had been derived from standardized assessment gear commonly utilized in psychiatric practice, and the data had been accumulated from digital scientific information.

2.5. ***Statistical Analysis.***

To explore the impact of comorbid scientific situations on psychiatric diagnoses, we carried out chi-square exams to compare the frequency and distribution of specific psychiatric diagnoses among the two groups (with and without comorbidities). This statistical evaluation allowed us to figure out any vast differences in the superiority of psychiatric disorders based totally on the presence or absence of clinical comorbidities.

We conducted logistic regression analyses to assess the likelihood of polypharmacy and the threat of unfavorable drug interactions in the groups with comorbid medical conditions compared to the institutions without comorbidities. Logistic regression allowed us to version the relationships between the presence of clinical comorbidities and the likelihood of receiving more than one medicinal drug while controlling for demographic variables.

Analysis of variance (ANOVA) was employed to evaluate the treatment outcomes among the two corporations. ANOVA enabled us to assess whether there have been statistically considerable variations in symptom discounts and pleasant life improvements between patients with comorbid clinical situations and those without. Using this statistical approach, we aimed to discern the effect of clinical comorbidities on the effectiveness of psychiatric remedies while accounting for capacity confounding factors.

3. RESULTS.

A total of 200 patients were included in this study. At the initial stage, several 373 patients were examined for eligibility, however, 173 patients were excluded from this study due to not being eligible.

ffers an outline of the demographic characteristics of the study the populace, comparing people with comorbidities to those without. On average, patients with comorbid clinical situations (45.2 ± 12.3 years) were older than their counterparts without comorbidities (38.7 ± 9.8 years). Furthermore, thetable suggests that the gender distribution was quite similar in each group, with slightly higher numbers of women as compared to men in the comorbid group (60 females to 40 males) and slightly more men in the non-comorbid group when compared to women (80 males to 20 females).

Table 2 gives a perception of the prescription styles for medicinal drugs among people with comorbidities and those without. Notably, patients with comorbid clinical situations were prescribed a higher suggested variety of psychotropic medicines (2.5 ± 1.2) than those without comorbidities (2.0 ± 1.0). Additionally, the total wide variety of treatments, such as each psychotropic and medical medicinal drug, become notably greater for patients with comorbidities (5.7 ± 2.0) as compared to their opposite numbers without comorbidities (4.0 ± 1.5), indicating a higher medication burden in the presence of scientific comorbidities.

Table 3 illustrates the treatment effects for people with and without comorbidities. It indicates that people with comorbid scientific situations experienced a lower mean percent of symptom discount (45.5% ± 12.3%) compared to the ones without comorbidities (55.8% ± 9.5%), indicating that the presence of scientific comorbidities may be related to much lessfavorable symptom development. Furthermore, the table demonstrates that people with comorbidities had a decrease in excellent lifestyles rating (4.7 ± 1.2) on a scale of 1-10, instead of the ones without comorbidities who had a higher suggested score (6.2 ± 1.5),

Table 1: **Demographic Characteristics.**

Demographic Variable	**With Comorbidities (n=100)**	**Without Comorbidities (n=100)**
Age (Mean ± SD)	45.2 ± 12.3 years	38.7 ± 9.8 years
Gender (Male/Female)	40/60	80/20
Socioeconomic Status (Low/Middle/High)	32/48/20	24/60/16

Table 2: **Prescribed Medications.**

Medication Category	**With Comorbidities (Mean ± SD)**	**Without Comorbidities (Mean ± SD)**
Psychotropic Medications	2.5 ± 1.2	2.0 ± 1.0
Medical Medications	3.2 ± 1.5	2.0 ± 1.2
Total Medications	5.7 ± 2.0	4.0 ± 1.5

Table 3: **Treatment Outcomes.**

Treatment Outcome	**With Comorbidities (Mean ± SD)**	**Without Comorbidities (Mean ± SD)**
Symptom Reduction (%)	45.5% ± 12.3%	55.8% ± 9.5%
Quality of Life (Scale 1-10)	4.7 ± 1.2	6.2 ± 1.5

implying that comorbid scientific conditions may additionally negatively impact universal excellent of lifestyles within the context of psychiatric remedy.

Table 4 summarizes the fundamental statistical analyses performed on this examination. The outcomes of logistic regression evaluation reveal that people with comorbidities have been 2.14 instances much more likely to enjoy polypharmacy (95% CI: 1.64 - 2.78) and 1.78 instances much more likely to stand adverse drug interactions (95% CI: 1.34 - 2.37) as compared to those without comorbidities. These findings advocate a full-size affiliation between comorbid scientific conditions and medication-associated demanding situations. Additionally, the ANOVA outcomes reveal that patients with comorbidities had an extensive decrease in the percentage of symptom discount (-10.3%) compared to their counterparts without comorbidities (5.8%), signifying that comorbidities may also preclude psychiatric symptom improvement. Furthermore, there has been a marked difference in great of life, with patients with comorbidities experiencing an average decrease of 1.5 factors on a scale of 1-10. In contrast, the ones without comorbidities saw a growth of 2.2 points. These findings spotlight comorbid medical conditions' enormous impact on symptom reduction and exceptional-of-life results, as evidenced using the sizable p-values (<0.001).

4. DISCUSSION.

4.1. ***Impact on Diagnosis.***

The study's commentary that people with comorbid medical situations are more likely to enjoy not on time or much less correct psychiatric diagnoses corroborates findings from previous studies within the area. Advanced research has established that clinical comorbidities can confound

Table 4: **Statistical Analyses.**

Analysis	Outcome Measure	With Comorbidities (n=100)	Without Comorbidities (n=100)	p-value
Logistic Regression (Polypharmacy)	Odds Ratio (95% CI)	2.14 (1.64 - 2.78)	1.00 (Reference)	<0.001
Logistic Regression (Adverse Drug Interactions)	Odds Ratio (95% CI)	1.78 (1.34 - 2.37)	1.00 (Reference)	<0.01
ANOVA (Symptom Reduction)	Mean Difference	-10.3%	+5.8%	<0.001
ANOVA (Quality of Life)	Mean Difference	-1.5 (Scale 1-10)	+2.2 (Scale 1-10)	<0.001

psychiatric prognosis due to overlapping signs and symptoms or the overlaying of psychiatric signs and symptoms via clinical situations [7-9]. This consistency throughout studies underscores the undertaking that clinicians face while navigating the complex interplay among clinical and psychiatric symptoms. It reinforces the significance of thorough assessment and an excessive index of suspicion while evaluating individuals with comorbidities to ensure that psychiatric problems aren't ignored or misdiagnosed.

4.2. ***Medication Management Challenges.***

The study's revelation of a better medicinal drug burden, which includes extended polypharmacy and an increased hazard of unfavorable drug interactions among people with comorbidities, aligns with earlier research findings. Past studies have often suggested similar demanding situations in medicinal drug control for patients with psychiatric and scientific conditions [10-12]. The elevated prescription of multiple medications can lead to complicated treatment regimens, capacity aspect consequences, and decreased medicinal drug adherence. These issues had been nicely documented within the literature, emphasizing the want for cautious remedy choice, monitoring, and affected person education to mitigate the risks related to polypharmacy.

4.3. ***Treatment Outcomes and Quality of Life.***

Comparing the study's outcome with previous research, a regular pattern emerges [13-16]. Individuals with comorbid scientific conditions tend to experience less favorable treatment consequences, consisting of decreased fees of symptom discounts and decreased satisfaction with lifestyles. Previous research studies have regularly reported similar disparities, emphasizing the multifaceted demanding situations of patients with concurrent clinical and psychiatric problems [13-16]. These challenges can vary from difficulties in dealing with signs and symptoms efficiently to the effect of comorbidities on general well-being. The consistent findings across several studies underline the vital significance of addressing those issues in clinical practice.

4.4. ***Implications for Integrated Care.***

Collectively, the findings from the study, alongside preceding research, underscore the pressing want for included care fashions that take into account each psychiatric and medical component of patient care. Integrated care has been proposed as a promising technique to cope with the complicated healthcare needs of people with comorbidities. Previous research has shown that collaborative efforts among healthcare companies from exceptional specialties can cause stepped-forward patient effects, higher medicinal drug control, and more desirable typical well-being [17-19]. The

study reinforces these findings, emphasizing that incorporated care models ought to be a concern in healthcare structures to provide comprehensive and tailor-made aid to people dealing with the challenges of concurrent medical and psychiatric conditions.

The study's findings align with previous studies in highlighting the giant effect of comorbid clinical conditions on psychiatric prognosis, remedy control, remedy consequences, and satisfactory lifestyles. The consistency of those findings across studies underscores the urgency of adopting included and affected person-centered strategies to care. By evaluating our effects with the existing research frame, we reinforce the significance of addressing these challenges comprehensively and collaboratively within healthcare systems to improve the overall health and well-being of individuals navigating psychiatric and scientific comorbidities.

5. CONCLUSION.

In conclusion, this study illuminates the significant effect of comorbid clinical conditions on the prognosis, remedy, and universal well-being of patients with psychiatric issues. Our findings reveal that comorbidities complicate psychiatric diagnoses, boom medicinal drug burdens, and lead to less favorable treatment effects, such as reduced symptom remedy and decreased quality of existence. These insights underscore the urgent need for incorporated and patient-targeted healthcare tactics that consider both psychiatric and clinical elements of care. Moving ahead, healthcare vendors and policymakers ought to collaborate to develop complete strategies that deal with the unique, demanding situations posed by comorbid conditions, with the remaining aim of enhancing the holistic fitness and well-being of patients facing this complicated intersection of psychiatric and clinical challenges.

6. LIMITATIONS.

The limitations of this study include a small sample population who were included in this study. The findings of this study cannot be generalized for a larger sample population. Furthermore, the lack of a comparison group also poses a limitation for this study's findings.

7. RECOMMENDATION.

Further research is warranted to discover specific strategies for incorporated care and increase pointers for managing comorbidities in psychiatric settings.

8. ACKNOWLEDGEMENT.

We are thankful to the patients; without them, the study could not have been done. We are thankful to the supporting staff of our hospital who were involved in the patient care of the study group.

9. LIST OF ABBREVIATIONS.

ANOVA- analysis of variance

DSM- Diagnostic and Statistical Manual of Mental Disorders

SD- Standard Deviation

CI- Confidence Interval

10. SOURCE OF FUNDING.

The study was not funded.

11. CONFLICT OF INTEREST.

The authors report no conflicts of interest in this work.

12. PUBLISHER DETAILS.

Publisher: Student's Journal of Health Research (SJHR)
(ISSN 2709-9997) Online
Category: Non-Governmental & Non-profit Organization
Email: studentsjournal2020@gmail.com
WhatsApp: +256775434261
Location: Wisdom Centre, P.O.BOX. 148, Uganda, East Africa.

13. REFERENCES.

1. Assmann, N., Fassbinder, E., Schaich, A., Lee, C. W., Boterhoven de Haan, K., Rijkeboer, M., & Arntz, A. (2021). Differential Effects of Comorbid Psychiatric Disorders on Treatment Outcome in Posttraumatic Stress Disorder from Childhood Trauma. *Journal of Clinical Medicine*, *10*(16), 3708. https://doi.org/10.3390/jcm10163708
2. Bélanger, L., Harvey, A. G., Fortier-Brochu, É., Beaulieu-Bonneau, S., Eidelman, P., Talbot, L., Ivers, H., Hein, K., Lamy, M., Soehner, A. M., Mérette, C., & Morin, C. M. (2016). Impact of Comorbid Anxiety and Depressive Disorders on Treatment Response to Cognitive Behavior Therapy for Insomnia. *Journal of Consulting and Clinical Psychology*, *84*(8), 659–667. https://doi.org/10.1037/ccp0000084
3. Briskman, I., Bar, G., Boaz, M., & Shargorodsky, M. (2012). Impact of Comorbid Mental Illness on the Diagnosis and Management of Patients Hospitalized for Medical Conditions in a General Hospital. *The International Journal of Psychiatry in Medicine*, *43*(4), 339–348. https://doi.org/10.2190/pm.43.4.d
4. Burns, L., Teesson, M., & O'Neill, K. (2005). The impact of comorbid anxiety and depression on alcohol treatment outcomes. *Addiction*, *100*(6), 787–796. https://doi.org/10.1111/j.1360-0443.2005.001069.x
5. Cramer, J. A., Blum, D., Fanning, K., & Reed, M. (2004). The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. *Epilepsy & Behavior*, *5*(3), 337–342. https://doi.org/10.1016/j.yebeh.2004.01.010
6. Devinsky, O. (2003). Psychiatric comorbidity in patients with epilepsy: implications for diagnosis and treatment. *Epilepsy & Behavior*, *4*, 2–10. https://doi.org/10.1016/j.yebeh.2003.10.002
7. Diebold, B. G., Lavian, J. D., Murray, D. D., Liu, S., Shah, N. P., Beyer, G. A., Segreto, F. A., Bloom, L. R., Vasquez-Montes, D., Day, L. M., Hollern, D. A., Horn, S. R., Naziri, Q., Cukor, D., Passias, P. G., & Paulino, C. B. (2018). *The Impact of Comorbid Mental Health Disorders on Complications Following Adult Spinal Deformity Surgery With Minimum 2-Year Surveillance*. *43*(17), 1176–1183. https://doi.org/10.1097/brs.0000000000002583
8. Jerrell, J. M., McIntyre, R. S., & Tripathi, A. (2010). A Cohort Study of the Prevalence and Impact of Comorbid Medical Conditions in Pediatric Bipolar Disorder. *The Journal of Clinical Psychiatry*, *71*(11), 1518–1525. https://doi.org/10.4088/jcp.09m05585ora
9. Kaplan, A., Szefler, S. J., & Halpin, D. M. G. (2020). Impact of comorbid conditions on asthmatic adults and children. *Npj Primary Care Respiratory Medicine*, *30*(1). https://doi.org/10.1038/s41533-020-00194-9
10. Katon, W., & Ciechanowski, P. (2002). Impact of major depression on chronic medical illness. *Journal of Psychosomatic Research*, *53*(4), 859–863. https://doi.org/10.1016/s0022-3999(02)00313-6
11. Launders, N., Dotsikas, K., Marston, L., Price, G., Osborn, D. P. J., & Hayes, J.

F. (2022). The impact of comorbid severe mental illness and common chronic physical health conditions on hospitalization: A systematic review and meta-analysis. *PLOS ONE*, *17*(8), e0272498. https://doi.org/10.1371/journal.pone.0272498

12. McEvoy, P. M., & Shand, F. (2008). The effect of comorbid substance use disorders on treatment outcome for anxiety disorders. *Journal of Anxiety Disorders*, *22*(6), 1087–1098. https://doi.org/10.1016/j.janxdis.2007.11.007
13. Merikangas, K. R., Ames, M., Cui, L., Stang, P. E., Ustun, T. B., Von Korff, M., & Kessler, R. C. (2007). The Impact of Comorbidity of Mental and Physical Conditions on Role Disability in the US Adult Household Population. *Archives of General Psychiatry*, *64*(10), 1180. https://doi.org/10.1001/archpsyc.64.10.1180
14. Merikangas, K. R., & Kalaydjian, A. (2007). Magnitude and impact of comorbidity of mental disorders from epidemiologic surveys. *Current Opinion in Psychiatry*, *20*(4), 353–358. https://doi.org/10.1097/yco.0b013e3281c61dc5
15. Mittal, D., Fortney, J. C., Pyne, J. M., Edlund, M. J., & Wetherell, J. L. (2006). Impact of Comorbid Anxiety Disorders on Health-Related Quality of Life Among Patients With Major Depressive Disorder. *Psychiatric Services*, *57*(12), 1731–1737. https://doi.org/10.1176/ps.2006.57.12.1731
16. Modesto-Lowe, V., & Kranzler, H. R. (1999). Diagnosis and treatment of alcohol-dependent patients with comorbid psychiatric disorders. *Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse and Alcoholism*, *23*(2), 144–149. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760422/
17. Newman, D. L., Moffitt, T. E., Caspi, A., & Silva, P. A. (1998). Comorbid mental disorders: Implications for treatment and sample selection. *Journal of Abnormal Psychology*, *107*(2), 305–311. https://doi.org/10.1037/0021-843x.107.2.305
18. Piette, J. D., & Kerr, E. A. (2006). The Impact of Comorbid Chronic Conditions on Diabetes Care. *Diabetes Care*, *29*(3), 725–731. https://doi.org/10.2337/diacare.29.03.06.dc05-2078
19. Richardson, L. P., Russo, J. E., Lozano, P., McCauley, E., & Katon, W. (2008). The effect of comorbid anxiety and depressive disorders on health care utilization and costs among adolescents with asthma. *General Hospital Psychiatry*, *30*(5), 398–406. https://doi.org/10.1016/j.genhosppsych.2008.06.004